StockMarketWire.com - Respiratory diseases focused Verona Pharma said it had made two senior appointments to lead a clinical trial of a treatment for chronic obstructive pulmonary disease.

Nina Church had joined as executive director of global clinical development and Nancy Herje as senior director of clinical operations.

'We believe ensifentrine, with its unique mode of action and clinical profile, has a very attractive commercial potential,' chief executive Anders Karlsson said.

'We plan to complete our Phase 2 program with nebulized ensifentrine with data expected around year end and to enter pivotal Phase 3 trials in 2020.'




Story provided by StockMarketWire.com